FSD Pharma: Developing Novel Solutions for Brain & Inflammatory Disorders
FSD Pharma (CSE: HUGE, NASDAQ: HUGE) is bringing innovative neuro and inflammatory disorders therapies to millions of patients in need.
FSD Pharma is bringing innovative neuro and inflammatory disorders therapies to millions of patients in need.
FSD Pharma, with only 38.4 million shares issued/outstanding, is a biotechnology company with three drug candidates in different stages of development.
FSD BioSciences, Inc. (“FSD BioSciences”), a wholly-owned subsidiary, is focused on pharmaceutical research and development of its lead compound, ultra-micronized palmitoyl ethylamine (“PEA”) or FSD-PEA (formerly called FSD-201). Lucid Psycheceuticals Inc. (“Lucid”), a wholly-owned subsidiary, is focused on the research and development of its lead compounds, Lucid-PSYCH (formerly Lucid-201) and Lucid-MS (formerly Lucid-21-302). Lucid PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders.
For more information on FSD Pharma Inc. (CSE: HUGE, NASDAQ: HUGE) please click the request investor info button.
Latest Articles
.png)
Hot Companies
You might also like
BluEnergies: Could Liberia’s Undrilled Harper Basin Hold a Major Deepwater Oil Discovery?
BluEnergies is targeting a frontier deepwater oil opportunity offshore Liberia, where the company holds approximately 2.2 million acres in the undrilled Harper Basin alongside supermajor TotalEnergies.
